BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17141785)

  • 21. Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion.
    Wredling R; Liu D; Lins PE; Adamson U
    Diabete Metab; 1991; 17(5):456-9. PubMed ID: 1752346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reduction of lipoproteins with apoAI but without apoAII (LpAI) in non-insulin-dependent diabetic patients].
    Barkia A; Zouari N; Khrouf W; Ellouz F; Zouaghi H
    Ann Biol Clin (Paris); 1996; 54(2):83-6. PubMed ID: 8763631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin resistance in multiple tissues in patients with type 1 diabetes mellitus on long-term continuous subcutaneous insulin infusion therapy.
    Donga E; van Dijk M; Hoogma RP; Corssmit EP; Romijn JA
    Diabetes Metab Res Rev; 2013 Jan; 29(1):33-8. PubMed ID: 22936679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.
    Hedman CA; Frystyk J; Lindström T; Oskarsson P; Arnqvist HJ
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):58-62. PubMed ID: 23865977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fasting and postprandial plasma glucose and peripheral insulin levels in insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus subjects during continuous intraperitoneal versus subcutaneous insulin delivery.
    Hermans MP; van Ypersele de Strihou M; Ketelslegers JM; Squifflet JP; Buysschaert M
    Transplant Proc; 1995 Dec; 27(6):3329-30. PubMed ID: 8539974
    [No Abstract]   [Full Text] [Related]  

  • 26. Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
    Pérez-Méndez O; Duhal N; Lacroix B; Bonte JP; Fruchart JC; Luc G
    Clin Chim Acta; 2006 Jun; 368(1-2):149-54. PubMed ID: 16487502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diabetes therapy with continuous insulin infusion by a portable pump: metabolic effects of short-term treatment and long-term results in problem patients].
    Schernthaner G; Graninger W; Kwasny W; Prager R; Otto C
    Acta Med Austriaca; 1982; 9(5-6):205-13. PubMed ID: 6762034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre- and postprandial hyperinsulinemia during insulin pump treatment; role of the subcutaneous bolus and basal infusion.
    Olsson PO; Jorfeldt L; Arnqvist H; Gerhardsson P
    Diabetes Res; 1991 Feb; 16(2):55-61. PubMed ID: 1817806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of optimal glycaemic control with continuous subcutaneous insulin infusion on energy expenditure in type I diabetes mellitus.
    Leslie P; Jung RT; Isles TE; Baty J; Newton RW; Illingworth P
    Br Med J (Clin Res Ed); 1986 Nov; 293(6555):1121-6. PubMed ID: 3094802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Normal HDL-apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy.
    Toledo-Ibelles P; Franco M; Carreón-Torres E; Luc G; Tailleux A; Vargas-Alarcón G; Fragoso JM; Aguilar-Salinas C; Luna-Luna M; Pérez-Méndez O
    Metabolism; 2013 Apr; 62(4):492-8. PubMed ID: 23089050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus.
    Selam JL; Kashyap M; Alberti KG; Lozano J; Hanna M; Turner D; Jeandidier N; Chan E; Charles MA
    Metabolism; 1989 Sep; 38(9):908-12. PubMed ID: 2671601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes.
    Albert SG; Oiknine RF; Parseghian S; Mooradian AD; Haas MJ; McPherson T
    Diabetes Care; 2007 Nov; 30(11):2800-3. PubMed ID: 17682119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of unstable diabetes with a portable insulin-infusion pump (author's transl)].
    Talaulicar M; Willms B
    Dtsch Med Wochenschr; 1982 Mar; 107(11):419-23. PubMed ID: 7037348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study.
    Nimri R; Weintrob N; Benzaquen H; Ofan R; Fayman G; Phillip M
    Pediatrics; 2006 Jun; 117(6):2126-31. PubMed ID: 16740856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetics treated with continuous subcutaneous insulin infusion pumps.
    Foley-Nolan D; Foley-Nolan A; Temperley D; Devlin J
    Ir Med J; 1989 Dec; 82(4):159-60. PubMed ID: 2516015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery.
    Selam JL; Kashyap ML; Gupta AK; Turner D; Wong ND; Lozano JL; Charles MA
    Metabolism; 1994 Jun; 43(6):665-9. PubMed ID: 8201953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
    Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.
    Hildebrandt P
    Dan Med Bull; 1991 Aug; 38(4):337-46. PubMed ID: 1914533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus.
    Frénais R; Ouguerram K; Maugeais C; Mahot P; Charbonnel B; Magot T; Krempf M
    Atherosclerosis; 2001 Jul; 157(1):131-5. PubMed ID: 11427212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.